Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kyowa Kirin CoKYKOF -8.23%84 Days Sales Outstanding is 85.30 as of Jun. 2026, which is 19% below its 10-year median of 104.85. GuruFocus rates KYKOF with a GF Score™ of 84/100 and a GF Value™ of $15.94 (Fairly Valued). Among 947 Drug Manufacturers companies, Kyowa Kirin Co ranks worse than 75.82% on this metric.
Kyowa Kirin Co's average Accounts Receivable for the
three
months ended in Jun. 2026 was $852 Mil. Kyowa Kirin Co's Revenue for the
three
months ended in Jun. 2026 was $911 Mil.
Hence, Kyowa Kirin Co's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 85.30.
The historical rank and industry rank for Kyowa Kirin Co's Days Sales Outstanding or its related term are showing as below:
KYKOF'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 95.26 Med: 104.85 Max: 138.04
Current: 105.54
During the past 13 years, Kyowa Kirin Co's highest Days Sales Outstanding was 138.04. The lowest was 95.26. And the median was 104.85.
KYKOF's Days Sales Outstanding is ranked worse than 75.82% of 947
companies
in the Drug Manufacturers industry
Industry Median: 71.98
vs KYKOF: 105.54
Kyowa Kirin Co's Days Sales Outstanding
declined
from Jun. 2025 (105.36) to Jun. 2026 (85.30).
Kyowa Kirin Co (OTCPK:KYKOF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Kyowa Kirin Co Days Sales Outstanding Related Terms
Kyowa Kirin Co Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Kyowa Kirin Co's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kyowa Kirin Co's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyowa Kirin Co Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kyowa Kirin Co's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Kyowa Kirin Co's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kyowa Kirin Co (KYKOF) has a Days Sales Outstanding of 85.30 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Kyowa Kirin Co and its competitors. This is 19% below median its historical median of 104.85. Over the past decade, Kyowa Kirin Co's Days Sales Outstanding has ranged from 95.26 to 138.04. According to the industry distribution chart, Kyowa Kirin Co ranks #718 out of 947 companies in the Drug Manufacturers industry, placing it in the top 75.8%.
Is Kyowa Kirin Co's Days Sales Outstanding too high?
Kyowa Kirin Co's current Days Sales Outstanding of 85.30 is 19% below median its 10-year median of 104.85. Over the past 10 years, this metric has ranged from a low of 95.26 to a high of 138.04. The Drug Manufacturers industry median Days Sales Outstanding is 71.98. Kyowa Kirin Co's value of 85.30 is 18.5% above this industry median. Based on the distribution chart, Kyowa Kirin Co ranks #718 out of 947 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Kyowa Kirin Co has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Kyowa Kirin Co's Days Sales Outstanding compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Kyowa Kirin Co ranks #718 out of 947 companies for Days Sales Outstanding. This places Kyowa Kirin Co in the lower half of its industry. The industry median Days Sales Outstanding is 71.98. Kyowa Kirin Co's value of 85.30 is 18.5% above this benchmark. Historically, Kyowa Kirin Co's own Days Sales Outstanding has ranged from 95.26 to 138.04 over the past decade. While the company's 10-year median is 104.85 vs. the industry median of 71.98, Kyowa Kirin Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.98, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kyowa Kirin Co's current Days Sales Outstanding of 85.30 is 18.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Kyowa Kirin Co and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kyowa Kirin Co's current Days Sales Outstanding is 85.30, which is 19% below median its own 10-year median of 104.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyowa Kirin Co stock overvalued right now?
Based on GuruFocus' analysis, Kyowa Kirin Co (KYKOF) is currently considered Fairly Valued. The stock's GF Value™ is $15.94, compared to a current price of $14.50 — trading 9% below its estimated fair value. The current Days Sales Outstanding is 85.30, which is 19% below median its 10-year median of 104.85 and 18.5% above the Drug Manufacturers industry median of 71.98. Kyowa Kirin Co's overall GF Score™ is 84/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Kyowa Kirin Co (KYKOF), the current Days Sales Outstanding is 85.30 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyowa Kirin Co (KYKOF) Overvalued in 2026?
Based on GuruFocus' analysis, Kyowa Kirin Co stock appears to be undervalued.
The current stock price of $14.50 is trading 9% below its estimated GF Value™ of $15.94.
GuruFocus considers Kyowa Kirin Co to be Fairly Valued.
Key valuation signals for KYKOF:
Days Sales Outstanding: 85.30 (19% below median its 10-year median of 104.85)
GF Value™: $15.94 vs. price of $14.50 (9% below fair value)
Industry Position: 18.5% above the Drug Manufacturers median (#718 of 947)
No single metric tells the full story. See the KYKOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyowa Kirin Co Ltd is engaged in research, development, manufacturing, sales, import and export of prescription pharmaceuticals. Its products include KHK4083/AMG 451, rocatinlimab; ziftomenib; OTL-203 KK8398, infigratinib; KHK4951, tivozanib; OTL-201; KK4277; KK2260; KK2269; KK2845; and KK8123.
84GF Score
Get the complete analysis for KYKOF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KYKOF has been successfully added to your 
